AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04530448
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour. Sodium bicarbonate 8.4% solution should not exceed 900 ml (4 boluses) in 24 hours.
Trial: NCT05088070
Drug: SPH 3348
RxNorm normalized name: SPH-3127
DrugBank: SPH-3127 (DB19108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of 8mg SPH3348 will be orally administered once a day with empty stomach
Trial: NCT05088070
Drug: SPH 3348
RxNorm normalized name: SPH-3127
DrugBank: SPH-3127 (DB19108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of 40mg SPH3348 will be orally administered once a day with empty stomach
Trial: NCT05088070
Drug: SPH 3348
RxNorm normalized name: SPH-3127
DrugBank: SPH-3127 (DB19108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
Trial: NCT05088070
Drug: SPH 3348
RxNorm normalized name: SPH-3127
DrugBank: SPH-3127 (DB19108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
Trial: NCT05088070
Drug: SPH 3348
RxNorm normalized name: SPH-3127
DrugBank: SPH-3127 (DB19108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
Trial: NCT05088070
Drug: SPH 3348
RxNorm normalized name: SPH-3127
DrugBank: SPH-3127 (DB19108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 tablets of 40mg SPH3348 will be orally administered once a day with empty stomach
Trial: NCT02384759
Drug: aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03224585
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - anakinra 100 mg subcutaneous injections daily for 4 days
Trial: NCT02267226
Drug: Octafibrin
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01223326
Drug: Acetylcysteine (NAC)
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion
Trial: NCT01223326
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Na Cl 0.9% infusion
Trial: NCT03674658
Drug: Propafenone
RxNorm normalized name: Propafenone
DrugBank: Propafenone (DB01182)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, TID
Trial: NCT03574428
Drug: GNbAC1
RxNorm normalized name: Immunoglobulin G4, anti-(multiple sclerosis-associated retrovirus viral envelope protein) (human-mus musculus monoclonal gnbac1 heavy chain), disulfide with human-mus musculus monoclonal gnbac1 kappa-chain, dimer
DrugBank: Temelimab (DB15634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal Antibody infused i.v.
Trial: NCT03434418
Drug: osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg oral administration daily
Trial: NCT03706300
Drug: Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02095509
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug class: Low-molecular weight heparin
Trial: NCT01722435
Drug: Opiate Substitution Treatment
RxNorm normalized name: hydroxypropyl cellulose, low substituted
DrugBank: Hydroxypropyl cellulose (DB00840)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01992562
Drug: Ziconotide
RxNorm normalized name: Ziconotide
DrugBank: Ziconotide (DB06283)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02153060
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
Trial: NCT02153060
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
Trial: NCT00250185
Drug: Sodium Nitrate
RxNorm normalized name: Sodium Nitrate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01753401
Drug: Acthar
RxNorm normalized name: Acthar
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day
Trial: NCT02309515
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04150172
Drug: Rebamipide SR 150mg
RxNorm normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Test drug
Trial: NCT04150172
Drug: Rebamipide IR 100mg
RxNorm normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Reference Drug
Trial: NCT00316238
Drug: olanzapine-RAIM
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02942017
Drug: SAGE-547 90 μg/kg/h
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of SAGE-547
Trial: NCT02691923
Drug: Fluorescein
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02691923
Drug: Fluorescein + ALA
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01157793
Drug: r-hGH
RxNorm normalized name: pantolactone, (R)-
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hGH at a dose of 0.15-1.00 mg/day administered for 48 weeks by s.c. route
Trial: NCT01157793
Drug: r-hGH
RxNorm normalized name: pantolactone, (R)-
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initially no treatment for the first 24 weeks followed by administration of r-hGH at a dose of 0.15 1.00 mg/day for the next 24 weeks, by s.c. route
Trial: NCT04405245
Drug: Latanoprost ophthalmic solution
RxNorm normalized name: Latanoprost Ophthalmic Solution
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost opthalmic solution to be dosed once daily
Trial: NCT02088177
Drug: Long-acting injectable naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vivitrol is a long-acting opioid antagonist which blocks opioid agonists from binding at opioid receptors. It be administered as described above.
Trial: NCT02825212
Drug: Harvoni
RxNorm normalized name: Harvoni
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis
Trial: NCT01847456
Drug: human insulin as nasal spray
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02825212
Drug: Epclusa
RxNorm normalized name: Epclusa
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.
Trial: NCT00011505
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01953913
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patient will receive afatinib once daily
Trial: NCT03469323
Drug: Succinylcholine
RxNorm normalized name: Succinylcholine
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giving mini-dose succinylcholine to facilitate lung collapse during nonintubated VATS.
Trial: NCT02703350
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SC
Trial: NCT00345982
Drug: Serdolect
RxNorm normalized name: Serdolect
DrugBank: Sertindole (DB06144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg, 12 weeks
Trial: NCT01618162
Drug: insulin degludec/liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
Trial: NCT04229836
Drug: Tildrakizumab 100 mg Solution for Injection
DrugBank: Tildrakizumab (DB14004)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be treated with tildrakizumab 100 mg.
Trial: NCT01189279
Drug: bimatoprost Formulation A
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
Trial: NCT01189279
Drug: bimatoprost Formulation B
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
Trial: NCT00005014
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01189279
Drug: bimatoprost Formulation C
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
Trial: NCT01523054
Drug: Metoprolol- Toprol XL
RxNorm normalized name: metoprolol Extended Release Oral Tablet [Toprol]
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended release tablet, 200mg once daily for 4 days
Trial: NCT01523054
Drug: Metoprolol- Lopressor
RxNorm normalized name: metoprolol Oral Tablet [Lopressor]
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
Trial: NCT04557072
Drug: Selective alpha-1-antagonist
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients treated with selective alpha-blockade (prazosin, terazosin, doxazosin)
Trial: NCT04557072
Drug: Non-selective alpha-1-antagonist
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients treated with non-selective alpha-blockade (phenoxybenzamine)
Trial: NCT01487811
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose administrated subcutaneously (s.c., under the skin)
Trial: NCT00338884
Drug: Sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
Trial: NCT02750254
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02750254
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02750254
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02750254
Drug: Granulocyte-colony stimulating factor
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02750254
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03370562
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of 10 mcg intravenous dexmedetomidine
Trial: NCT02581969
Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
RxNorm normalized name: factor VIII Injection [Recombinate]
DrugBank: PEGylated Recombinant Factor VIII (DB16093)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered 20-30 IU/kg 3 times a week
Trial: NCT02581969
Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
RxNorm normalized name: factor VIII Injection [Recombinate]
DrugBank: PEGylated Recombinant Factor VIII (DB16093)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered only for bleeding episodes
Trial: NCT04130698
Drug: transdermal nicotine patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will use the patch for 8 weeks as outlined by the recommended usage for steps 1-3 going from 21mg for 4 weeks, 14mg for 1 week, and 7mg for 1 week.
Trial: NCT01844778
Drug: Tobramycin inhalation solution
RxNorm normalized name: Tobramycin Inhalation Solution
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation solution was administered via nebuliser
Trial: NCT01844778
Drug: Colistimethate
RxNorm normalized name: colistimethate
DrugBank: Colistimethate (DB01111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistimethate was administered via nebuliser.
Trial: NCT00037154
Drug: Saw Palmetto
RxNorm normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00989781
Drug: recombinant human chorionic gonadotropin
RxNorm normalized name: Recombinant human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards
Trial: NCT00989781
Drug: Recombinant human follicle stimulating hormone
RxNorm normalized name: Recombinant human follicle stimulating hormone beta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.
Trial: NCT00989781
Drug: Adrenocorticotropin
RxNorm normalized name: Adrenocorticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.
Trial: NCT00989781
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be given prior to ACTH infusion test.
Trial: NCT00989781
Drug: Glucose
RxNorm normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will undergo 3 oral glcuose tolerance tests.
Trial: NCT01532869
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 162 mg subcutaneously weekly, Weeks 0-48
Trial: NCT01532869
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 162 mg subcutaneously weekly, Week 48-96
Trial: NCT02562807
Drug: TAS-303 18mg single-dose
RxNorm normalized name: TAS-303
DrugBank: TAS-303 (DB18808)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02562807
Drug: TAS-303 9mg single-dose
RxNorm normalized name: TAS-303
DrugBank: TAS-303 (DB18808)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02879578
Drug: Valbenazine
RxNorm normalized name: Valbenazine
DrugBank: Valbenazine (DB11915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04447326
Drug: Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles Endostar: 7.5 mg/m2/d, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles
Trial: NCT04133233
Drug: ILT101
RxNorm normalized name: ILT101
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)
Trial: NCT04181385
Drug: Olanzapine 10 milligram
RxNorm normalized name: Product containing precisely olanzapine 10 milligram/1 each conventional release oral tablet (clinical drug)
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral olanzapine capsule
Trial: NCT04230044
Drug: Perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel tablets.
Trial: NCT04181385
Drug: Bromocriptine 5 milligram
RxNorm normalized name: bromocriptine 5 MG
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral bromocriptine capsule
Trial: NCT03385928
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational product given within 2 hours of symptom onset
Trial: NCT00224874
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept \[25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks\].
Trial: NCT00224874
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) \[20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks\].
Trial: NCT00224874
Drug: Denileukin Diftitox
RxNorm normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Denileukin Diftitox (ONTAK®) \[9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19\].
Trial: NCT00224874
Drug: Pentostatin
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentostatin \[1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17
Trial: NCT02519010
Drug: Amlodipine/Valsartan
RxNorm normalized name: AMLODIPINE/VALSARTAN
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 tablet contains Amlodipine 10 mg \&valsartan 160 mg
Trial: NCT02519010
Drug: Exforge
RxNorm normalized name: Exforge
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 tablet contains Amlodipine 10 mg \&valsartan 160 mg
Trial: NCT00911534
Drug: rabeprazole sodium
RxNorm normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.
Trial: NCT00338416
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00269126
Drug: fluticasone propionate/salmeterol combination DISKUS
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00269126
Drug: salmeterol xinafoate
RxNorm normalized name: Salmeterol Xinafoate
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01426165
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8 grams over 4 or 8 hours depending on randomization
Trial: NCT01047748
Drug: intra-fetal digoxin injection
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single transabdominal injection of digoxin 1 mg into the fetus
Trial: NCT01047748
Drug: intra-amniotic digoxin injection
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single transabdominal injection of digoxin 1 mg into the amniotic fluid
Trial: NCT02982486
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 1 mg/kg every 6 weeks
Trial: NCT02982486
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ninolumab 240 mg IV every 2 weeks
Trial: NCT00004310
Drug: Clomipramine
RxNorm normalized name: Clomipramine
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04195919
Drug: Evogliptin 5mg
RxNorm normalized name: alogliptin 12.5 MG
DrugBank: Evogliptin (DB12625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive Single oral administration of Evogliptin 5mg on day1
Trial: NCT04195919
Drug: Evogliptin 5mg
RxNorm normalized name: alogliptin 12.5 MG
DrugBank: Evogliptin (DB12625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1(1d,After hemodialysis) → Wash-out period → Period 2(15d,Before hemodialysis)~Hemodialysis patients receive Single oral administration of Evogliptin 5mg on day1 and day15 With a 14-day washout period
Trial: NCT04702568
Drug: Eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered at stable dose at the time of study entry
Trial: NCT04702568
Drug: Ravulizumab
RxNorm normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered at stable dose at the time of study entry